Merus N.V. Stock

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-14 pm EDT 5-day change 1st Jan Change
56.55 USD -1.91% Intraday chart for Merus N.V. +6.90% +105.64%
Sales 2024 * 40.97M Sales 2025 * 53.57M Capitalization 3.75B
Net income 2024 * -176M Net income 2025 * -223M EV / Sales 2024 * 91.4 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 69.9 x
P/E ratio 2024 *
-19.4 x
P/E ratio 2025 *
-16.6 x
Employees 201
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.49%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.91%
1 week+6.90%
Current month+6.22%
1 month+26.31%
3 months+26.79%
6 months+123.69%
Current year+105.64%
More quotes
1 week
51.71
Extreme 51.71
59.66
1 month
42.60
Extreme 42.6
61.61
Current year
27.11
Extreme 27.11
61.61
1 year
19.81
Extreme 19.805
61.61
3 years
12.03
Extreme 12.03
61.61
5 years
10.18
Extreme 10.18
61.61
10 years
7.26
Extreme 7.255
61.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 19-06-11
Director of Finance/CFO 63 16-04-30
Chief Tech/Sci/R&D Officer - 16-11-30
Members of the board TitleAgeSince
Director of Finance/CFO 63 16-04-30
Director/Board Member 66 21-05-27
Director/Board Member 63 20-06-29
More insiders
Date Price Change Volume
24-06-14 56.55 -1.91% 566,651
24-06-13 57.65 +1.75% 1,238,275
24-06-12 56.66 -0.79% 949,676
24-06-11 57.11 +7.09% 1,585,152
24-06-10 53.33 +0.81% 793,260

Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT

More quotes
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
56.55 USD
Average target price
83.36 USD
Spread / Average Target
+47.42%
Consensus